Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone

Gayatri Sathyan, Emily Xu, John Thipphawong, Suneel K Gupta, Gayatri Sathyan, Emily Xu, John Thipphawong, Suneel K Gupta

Abstract

Background: The purpose of this study was investigate the dose proportionality of a novel, once-daily, controlled-release formulation of hydromorphone that utilizes the OROS Push-Pull osmotic pump technology.

Methods: In an open-label, four-way, crossover study, 32 healthy volunteers were randomized to receive a single dose of OROS hydromorphone 8, 16, 32, and 64 mg, with a 7-day washout period between treatments. Opioid antagonism was provided by three or four doses of naltrexone 50 mg, given at 12-hour intervals pre- and post-OROS hydromorphone dosing. Plasma samples for pharmacokinetic analysis were collected pre-dose and at regular intervals up to 48 hours post-dose (72 hours for the 64-mg dose), and were assayed for hydromorphone concentration to determine peak plasma concentration (Cmax), time at which peak plasma concentration was observed (Tmax), terminal half-life (t1/2), and area under the concentration-time curve for zero to time t (AUC0-t) and zero to infinity (AUC0-infinity). An analysis of variance (ANOVA) model on untransformed and dose-normalized data for AUC0-t, AUC0-infinity, and Cmax was used to establish dose linearity and proportionality.

Results: The study was completed by 31 of 32 subjects. Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose. Regression analyses of Cmax, AUC0-48, and AUC0-infinity by dose indicated that the relationship was linear (slope, P < or = 0.05) and that the intercept did not differ significantly from zero (P > 0.05). Similar analyses with dose-normalized parameters also indicated that the slope did not differ significantly from zero (P > 0.05).

Conclusion: The pharmacokinetics of OROS hydromorphone are linear and dose proportional for the 8, 16, 32, and 64 mg doses.

Trial registration: ClinicalTrials.gov NCT00398957.

Figures

Figure 1
Figure 1
Mean plasma hydromorphone concentrations over time after administration of single-dose OROS® hydromorphone.
Figure 2
Figure 2
Analyses of dose linearity with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose. Dashed lines represent 95% CI.
Figure 3
Figure 3
Analyses of dose proportionality with OROS® hydromorphone: (A) Cmax/dose; (B) AUC0–48/dose. Dashed lines represent 95% CI.

References

    1. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage. 2003;25:169–178. doi: 10.1016/S0885-3924(02)00643-7.
    1. Hill HF, Coda BA, Tanaka A, Schaffer R. Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesth Analg. 1991;72:330–336. doi: 10.1213/00000539-199103000-00009.
    1. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981;21:152–156.
    1. Parab PV, Ritschel WA, Coyle DE, Gregg RV, Denson DD. Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Dispos. 1988;9:187–199. doi: 10.1002/bod.2510090207.
    1. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005;29:S57–S66. doi: 10.1016/j.jpainsymman.2005.01.007.
    1. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987–1991. doi: 10.1002/jps.2600641218.
    1. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Jr., Dornseif BE, Damask MC. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355–368. doi: 10.1016/S0885-3924(02)00390-1.
    1. Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release nondeformable, oral dosage form (OROS®). A retrospective study. Drug Saf. 2002;25:1021–1033. doi: 10.2165/00002018-200225140-00004.
    1. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97:827–836. doi: 10.1097/00000542-200210000-00013.
    1. Summary of Product Characteristics for JURNISTA. ALZA Corporation, Mountain View, CA.; May 2006.
    1. Sathyan G, Xu E, Gupta S. Effect of food on the pharmacokinetic profile of OROS hydromorphone [abstract] IASP Press. 2005;632 Abstract 1796-P299.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する